Concentra Group Holdings Parent, Inc.
Concentra provides occupational health and related healthcare services to employers and their workers, as well as consumer health services. It operates 628 stand-alone occupational health centers in 41 states, 411 onsite health clinics at employer worksites in 44 states, and telemedicine services across 43 states and the District of Columbia. Its three operating segments are occupational health centers, onsite health clinics, and other businesses. Services include workers’ compensation injury care, physical therapy, employer examinations and screenings, preventive care, employer-sponsored primary care, and consumer urgent care. Other businesses include Concentra Telemed, Concentra Pharmacy, and Concentra Medical Compliance Administration. Concentra serves employers of all sizes through its centers and other businesses, and medium to large-sized employers through onsite clinics. It receives payments from workers’ compensation insurers, third-party administrators, self-insured employers, employers, and commercial insurance carriers; it also serves individual consumers. Concentra is headquartered in Addison, Texas.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CON in the last 7 days.
No SEC Form 4 filings for $CON in the last 30 days.
See all $CON insider activity →Stephens initiated coverage on Concentra Group (NYSE:CON) with an overweight rating and a $45 price target, citing its health model and growth prospects. The stock is near its 52-week high after a 95% YTD surge. Concentra reported Q2 revenue of $606M and raised its full-year outlook. S&P upgraded its rating to BB, and Jefferies initiated coverage with a Buy rating and $47 target.
Jefferies initiated coverage on Concentra Group (NYSE:CON) with a Buy rating and $47 price target, citing its market leadership and strong financials. The stock has surged 100% YTD. Concentra reported Q2 revenue of $606M, up 10% YoY, and raised its full-year outlook. S&P upgraded its credit rating to BB from BB-.
Biotech stocks BIIB, RTSN, CON, HNGE, and HSTM reached 52-week highs on October 12, 2026. BIIB hit $230.49 after positive clinical data for Litifilimab. RTSN rose 7% to $11.32 post-IPO. CON reported Q2 revenue growth of 10% to $606M. HNGE saw Q2 revenue rise 53% to $212M and acquired Cylinder Health. HSTM's Q2 revenue grew 12.5% to $83.7M.
Recent CON coverage spans financial news, market movers and corporate actions.
Analyst upgrade and higher price target suggest upside potential.
Analyst initiation and upgrade likely to drive buying interest.
Strong earnings and revenue growth support the price rally.
Bullish on strong revenue growth and outlook.
The CFO appointment signals continuity in financial strategy and may support investor confidence, but immediate price impact is expected to be modest.
AlphAI scores every news story that mentions CON with an AI model for sentiment and relevance, and aggregates insider trades from Concentra Group Holdings Parent, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stephens initiated coverage on Concentra Group (NYSE:CON) with an overweight rating and a $45 price target, citing its health model and growth prospects. The stock is near its 52-week high after a 95% YTD surge. Concentra reported Q2 revenue of $606M and raised its full-year outlook. S&P upgraded its rating to BB, and Jefferies initiated coverage with a Buy rating and $47 target.
2 min readJefferies initiated coverage on Concentra Group (NYSE:CON) with a Buy rating and $47 price target, citing its market leadership and strong financials. The stock has surged 100% YTD. Concentra reported Q2 revenue of $606M, up 10% YoY, and raised its full-year outlook. S&P upgraded its credit rating to BB from BB-.
2 min readBiotech stocks BIIB, RTSN, CON, HNGE, and HSTM reached 52-week highs on October 12, 2026. BIIB hit $230.49 after positive clinical data for Litifilimab. RTSN rose 7% to $11.32 post-IPO. CON reported Q2 revenue growth of 10% to $606M. HNGE saw Q2 revenue rise 53% to $212M and acquired Cylinder Health. HSTM's Q2 revenue grew 12.5% to $83.7M.
2 min readPacira BioSciences (PCRX) surged 44% to $36.46 after Vitaris agreed to acquire it for $1.65B. Veradermics (MANE) rose 14% to $136.72, while HealthStream (HSTM) gained 2% to $32.42. Concentra (CON) and Haemonetics (HAE) also hit 52-week highs on strong financials.
2 min readConcentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE September 8, 2026 Concentra Appoints Tanner Newton Chief Financial Officer Experienced Concentra leader brings deep knowledge of the company’s strategy, financial operations and investor community DALLAS--Concentra® (NYSE: CON), the
2 min readS&P Global Ratings upgraded Concentra Group Holdings (NYSE:CON) to BB from BB-, citing lower leverage and strong performance. The company's adjusted leverage fell below 3.5x in Q2, with projections improving to 3x by fiscal 2027. Concentra generated $250M in annual free operating cash flow and increased EBITDA by over $100M since fiscal 2024, driven by growth and cost controls. S&P maintained a stable outlook but noted potential downgrade risks.
1 min readConcentra Group Holdings Parent, Inc. (CON) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Stock Repurchase Agreement On August 21, 2026, Concentra Group Holdings Parent, Inc. (the “Company”) entered into a stock repurchase agreement (the “Stock Repurchase Agreement”) with Robert A. Ortenzio, chairman of the Company
2 min readORTENZIO ROBERT A sold (to issuer) 230,000 indirectly-held shares of Concentra Group Holdings Parent, Inc. (CON) at an average of $34.78 ($34.65–$35.65, $8.00M total) across 4 trades on 2026-08-21.
1 min readORTENZIO ROBERT A sold (to issuer) 770,000 shares of Concentra Group Holdings Parent, Inc. (CON) at $34.65 ($26.68M total) on 2026-08-21.
1 min readBiotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.
4 min read